ClinicalTrials.gg
Active, not recruitingNCT05462145PULSARUpdated Oct 6, 2026

Safety and Effectiveness of the Globe® Pulsed Field System for Treating Patients With Symptomatic Paroxysmal or Persistent Atrial Fibrillation

An interventional study of Globe Pulsed Field System in Paroxysmal Atrial Fibrillation and Persistent Atrial Fibrillation, sponsored by Kardium Inc.. Active, not recruiting at 17 sites in 4 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-06.

Sponsored by Kardium Inc. · Not applicable, Interventional, and Treatment

How we know

Updated Oct 6, 2026Primary completion movedStudy completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
549
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 993 studies in Atrial Fibrillation with a site in United States — 160 open to participants now, 220 under way, 15 of them phase 3. Atrial Fibrillation · United States.

Planned enrollment
128th of 679
549 · median 127
Started
2023
with 54 others
No phase
405 of 993
67 open now
Primary completion
2029-03
later than 189 of 219 live
Registered
796th of 993
by date

Among the 993 studies in Atrial Fibrillation with a site in United States, this one is the 128th largest by planned enrollment of the 679 interventional ones that give a count, is one of 55 that started in 2023, is one of 405 with no phase, reaches primary completion later than 189 of the 219 other live ones, and was the 796th registered.

Atrial Fibrillation

4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

160 of the 993 studies in Atrial Fibrillation with a site in United States are open now. Recruiting first, the newest first:

155 more — sign in →

All 160 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 993 studies in Atrial Fibrillation with a site in United States, or all of them as a file.
02

Study summary

This study will evaluate the safety and effectiveness of the Globe® Pulsed Field System for treating patients with symptomatic paroxysmal or persistent atrial fibrillation (AF).

03

Conditions studied

  • Paroxysmal Atrial Fibrillation
  • Persistent Atrial Fibrillation

Browse trials for

Keywords

  • Pulsed Field Ablation
  • Irreversible Electroporation
04

Who can participate

The criteria were revised on the registry on Oct 6, 2026. See what changed

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key inclusion criteria:

  • A diagnosis of recurrent symptomatic paroxysmal or persistent AF
  • Failure or intolerance of at least one antiarrhythmic drug (AAD) Class I or III or AAD naïve subjects

Key exclusion criteria:

  • Long-standing persistent AF (sustained >12 months)
  • Atrial fibrillation secondary to a reversible cause or of non-cardiac origin
  • History of thromboembolic events within the past six months
  • Myocardial infarction (MI)/percutaneous coronary intervention (PCI) within the last three months
  • Any cardiac surgery within the previous six months
  • Prior left atrial ablation or surgical procedure
  • Presence of an implanted cardiac device
  • (BMI) >40 kg/m\^2
  • (LVEF) \<35%
  • Anterior-posterior left atrial (LA) diameter >55mm
  • Right atrial minor-axis (transverse) diameter \<32mm for adjunctive cavotricuspid isthmus (CTI) ablation only
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
549 participants (estimated)

Study arms

  • Experimental
    Globe Pulsed Field System

    Device: Globe Pulsed Field System

Interventions

  • DeviceGlobe Pulsed Field System

    Ablation and atrial mapping with the Globe Pulsed Field System

06

What researchers measure

Primary outcomes

  1. Effectiveness endpoint

    Number of subjects with freedom from documented atrial fibrillation, atrial flutter, and atrial tachycardia (AF/AFL/AT) 12 months post-procedure.

    Time frame: 12 months

  2. Safety endpoint

    Rate of subjects presenting with one or more of the specified primary safety events within 7 days of the index ablation procedure.

    Time frame: 7 days

07

Study locations

17 sites
08

References and documents

Publications

  • Reddy VY, Kottkamp H, Calkins H, Nair DG, Sommer P, Hussein AA, Schumacher B, Dukkipati S, Neuzil P, Oza S, Woods C, Deyell MW, Osorio J, Verma A; PULSAR Investigators. Pulsed-Field Ablation to Enhance the Durability of Pulmonary Vein Isolation and Treat Paroxysmal Atrial Fibrillation. J Am Coll Cardiol. 2026 Apr 14;87(14):1747-1761. doi: 10.1016/j.jacc.2025.10.084. Epub 2026 Jan 21. PubMed 41563170 ↗
09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2023 (actual). Primary completion is estimated for Mar 2029, 72 months after the start.

Of 255 industry-sponsored interventional studies with no phase under Atrial Fibrillation, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 36. This study's planned 72 months is above that.

Counting every sponsor, half of 1,052 studies reached it within 33 months; a quarter within 18 and three quarters within 54.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 6, 2026: primary completion Sep 2026 → Mar 2029 and completion Sep 2026 → Mar 2029.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 13, 2022
First posted
Jul 18, 2022
StartActual
Mar 9, 2023
Primary completionEst.
Mar 2029was Sep 2026
CompletionEst.
Mar 2029was Sep 2026
Last update
Oct 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site removed
Show 1 removed
  • Doylestown Hospital · Doylestown, United States
Oct 6, 2026
Primary completion
Sep 2026→Mar 2029
Oct 6, 2026
Study completion
Sep 2026→Mar 2029
Oct 6, 2026
Eligibility
1 criterion edited, 1 added
What changed in the criteria
  • EditedFailure or intolerance of at least one antiarrhythmic drug (AAD) Class I or III or AAD naïve subjects
  • AddedRight atrial minor-axis (transverse) diameter <32mm for adjunctive cavotricuspid isthmus (CTI) ablation only
Oct 6, 2026
Show all 1 update
  1. Oct 6, 2026
    1 site removed
    Show 1 removed
    • Doylestown Hospital · Doylestown, United States
    Primary completion Sep 2026→Mar 2029
    Study completion Sep 2026→Mar 2029
    Eligibility 1 criterion edited, 1 added
    What changed in the criteria
    • EditedFailure or intolerance of at least one antiarrhythmic drug (AAD) Class I or III or AAD naïve subjects
    • AddedRight atrial minor-axis (transverse) diameter <32mm for adjunctive cavotricuspid isthmus (CTI) ablation only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05462145
Lead sponsor
Kardium Inc.
Responsible party
Sponsor
First posted
Jul 18, 2022
Start date
Mar 9, 2023
Primary completion
Mar 2029 (estimated)
Completion
Mar 2029 (estimated)
Last update
Oct 6, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion